Glioblastoma (GBM) is a devastating illness with a survival of <18 months; it touches people in the middle of their careers & lives. Guidelines list clinical trials as treatment of choice but only 7% of patients enroll. Our hypothesis is that if providers & patients are given a supporting tool, this rate can be significantly improved. The BTTF as curated AI option for ‘matchmaking’ the right clinical trial to the right patient aims to double this enrollment rate.